Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12
OBJECTIVESRecurrent hepatitis C virus (HCV) infection after liver transplantation (LT) is a major cause of transplant failure in HCV-positive patients. We retrospectively assessed the efficacy and safety of antiviral therapy and determined the factors influencing sustained virologic response (SVR) i...
Gespeichert in:
| Veröffentlicht in: | European journal of gastroenterology & hepatology 2008-08, Vol.20 (8), p.778-783 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 783 |
|---|---|
| container_issue | 8 |
| container_start_page | 778 |
| container_title | European journal of gastroenterology & hepatology |
| container_volume | 20 |
| creator | Raziorrouh, Bijan Jung, Maria-Christina Schirren, Carl Albrecht Loehe, Florian Thiel, Manfred Nitschko, Hans Diepolder, Helmut Ulsenheimer, Axel Heeg, Malte Zachoval, Reinhart Gruener, Norbert Hubert |
| description | OBJECTIVESRecurrent hepatitis C virus (HCV) infection after liver transplantation (LT) is a major cause of transplant failure in HCV-positive patients. We retrospectively assessed the efficacy and safety of antiviral therapy and determined the factors influencing sustained virologic response (SVR) in LT recipients.
METHODSBetween 1998 and 2007, we treated 36 LT recipients for hepatitis C cirrhosis and subsequent HCV recurrence (27 genotype 1 and 9 genotypes 2/3) with pegylated interferon α-2a (180 μg/week), pegylated interferon α-2b (1.5 μg/kg per week), or standard interferon α-2b (3 MIU 3X/week) plus ribavirin (600–1200 mg/day) for 48 weeks.
RESULTSSVR was achieved in seven of 27 (26%) of genotype 1 patients versus nine of nine (100%) genotype 2/3 patients (P=0.0001). Early virologic response at week 12 was associated with permanent viral clearance. Side effects included cytopenia and acute hearing loss, but rate of therapy withdrawal and dose reduction was low.
CONCLUSIONCombination therapy in patients with HCV reinfection after LT yields an excellent SVR rate in genotype 2/3 patients, but remains unsatisfactory in genotype 1 patients. Virologic response at week 12 (early virologic response) can determine whether therapy should be continued or not. |
| doi_str_mv | 10.1097/MEG.0b013e3282f762f8 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_MEG_0b013e3282f762f8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18617783</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3801-a0f69db9088fa461668a2dc86be8e39c4a87a9dcab06ac2abe3d62d3db186ef43</originalsourceid><addsrcrecordid>eNpdkMFqHDEMhk1pabZp36AUX3qcRLYntqe3sKRJIaWXFnobNB45O40zHmxvln2TPG4dsnShCEkH_f8v-Bj7KOBMQGfOv19dn8EAQpGSVnqjpbev2Eq0RjUX2prXbAXdRdvoTvw-Ye9y_gMgjBLmLTsRVgtjrFqxp8u5TI9TwsDLhhIue-5j4oncNiWaC9_QgmUqU-Zrjr5Q4mF6rLMknPMScC71HOcvPG9zwWmmkde4GOLd5GpMXuKciVd7ooClXkvkdzTHsl-Iy3PFcR6POix8R3TPhXzP3ngMmT4c9in79fXq5_qmuf1x_W19eds4ZUE0CF5349CBtR5bLbS2KEdn9UCWVOdatAa70eEAGp3EgdSo5ajGoTIg36pT1r7kuhRzTuT7JU0PmPa9gP4ZdF9B9_-DrrZPL7ZlOzzQeDQdyFbB54MAs8PgKy435X86Ca01Vsrj_10MlW6-D9sdpX5DGMqmB4BWGmUaCWBrATS1hVB_ARVAmzM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Raziorrouh, Bijan ; Jung, Maria-Christina ; Schirren, Carl Albrecht ; Loehe, Florian ; Thiel, Manfred ; Nitschko, Hans ; Diepolder, Helmut ; Ulsenheimer, Axel ; Heeg, Malte ; Zachoval, Reinhart ; Gruener, Norbert Hubert</creator><creatorcontrib>Raziorrouh, Bijan ; Jung, Maria-Christina ; Schirren, Carl Albrecht ; Loehe, Florian ; Thiel, Manfred ; Nitschko, Hans ; Diepolder, Helmut ; Ulsenheimer, Axel ; Heeg, Malte ; Zachoval, Reinhart ; Gruener, Norbert Hubert</creatorcontrib><description>OBJECTIVESRecurrent hepatitis C virus (HCV) infection after liver transplantation (LT) is a major cause of transplant failure in HCV-positive patients. We retrospectively assessed the efficacy and safety of antiviral therapy and determined the factors influencing sustained virologic response (SVR) in LT recipients.
METHODSBetween 1998 and 2007, we treated 36 LT recipients for hepatitis C cirrhosis and subsequent HCV recurrence (27 genotype 1 and 9 genotypes 2/3) with pegylated interferon α-2a (180 μg/week), pegylated interferon α-2b (1.5 μg/kg per week), or standard interferon α-2b (3 MIU 3X/week) plus ribavirin (600–1200 mg/day) for 48 weeks.
RESULTSSVR was achieved in seven of 27 (26%) of genotype 1 patients versus nine of nine (100%) genotype 2/3 patients (P=0.0001). Early virologic response at week 12 was associated with permanent viral clearance. Side effects included cytopenia and acute hearing loss, but rate of therapy withdrawal and dose reduction was low.
CONCLUSIONCombination therapy in patients with HCV reinfection after LT yields an excellent SVR rate in genotype 2/3 patients, but remains unsatisfactory in genotype 1 patients. Virologic response at week 12 (early virologic response) can determine whether therapy should be continued or not.</description><identifier>ISSN: 0954-691X</identifier><identifier>EISSN: 1473-5687</identifier><identifier>DOI: 10.1097/MEG.0b013e3282f762f8</identifier><identifier>PMID: 18617783</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins, Inc</publisher><subject>Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Genotype ; Graft Survival ; Hepacivirus - drug effects ; Hepacivirus - genetics ; Hepatitis C - drug therapy ; Hepatitis C - surgery ; Human viral diseases ; Humans ; Immunosuppressive Agents - therapeutic use ; Infectious diseases ; Interferon-alpha - adverse effects ; Interferon-alpha - therapeutic use ; Liver Transplantation ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Recurrence ; Retrospective Studies ; Ribavirin - adverse effects ; Ribavirin - therapeutic use ; Survival Analysis ; Treatment Outcome ; Viral diseases ; Viral hepatitis</subject><ispartof>European journal of gastroenterology & hepatology, 2008-08, Vol.20 (8), p.778-783</ispartof><rights>2008 Lippincott Williams & Wilkins, Inc.</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3801-a0f69db9088fa461668a2dc86be8e39c4a87a9dcab06ac2abe3d62d3db186ef43</citedby><cites>FETCH-LOGICAL-c3801-a0f69db9088fa461668a2dc86be8e39c4a87a9dcab06ac2abe3d62d3db186ef43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20487822$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18617783$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raziorrouh, Bijan</creatorcontrib><creatorcontrib>Jung, Maria-Christina</creatorcontrib><creatorcontrib>Schirren, Carl Albrecht</creatorcontrib><creatorcontrib>Loehe, Florian</creatorcontrib><creatorcontrib>Thiel, Manfred</creatorcontrib><creatorcontrib>Nitschko, Hans</creatorcontrib><creatorcontrib>Diepolder, Helmut</creatorcontrib><creatorcontrib>Ulsenheimer, Axel</creatorcontrib><creatorcontrib>Heeg, Malte</creatorcontrib><creatorcontrib>Zachoval, Reinhart</creatorcontrib><creatorcontrib>Gruener, Norbert Hubert</creatorcontrib><title>Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12</title><title>European journal of gastroenterology & hepatology</title><addtitle>Eur J Gastroenterol Hepatol</addtitle><description>OBJECTIVESRecurrent hepatitis C virus (HCV) infection after liver transplantation (LT) is a major cause of transplant failure in HCV-positive patients. We retrospectively assessed the efficacy and safety of antiviral therapy and determined the factors influencing sustained virologic response (SVR) in LT recipients.
METHODSBetween 1998 and 2007, we treated 36 LT recipients for hepatitis C cirrhosis and subsequent HCV recurrence (27 genotype 1 and 9 genotypes 2/3) with pegylated interferon α-2a (180 μg/week), pegylated interferon α-2b (1.5 μg/kg per week), or standard interferon α-2b (3 MIU 3X/week) plus ribavirin (600–1200 mg/day) for 48 weeks.
RESULTSSVR was achieved in seven of 27 (26%) of genotype 1 patients versus nine of nine (100%) genotype 2/3 patients (P=0.0001). Early virologic response at week 12 was associated with permanent viral clearance. Side effects included cytopenia and acute hearing loss, but rate of therapy withdrawal and dose reduction was low.
CONCLUSIONCombination therapy in patients with HCV reinfection after LT yields an excellent SVR rate in genotype 2/3 patients, but remains unsatisfactory in genotype 1 patients. Virologic response at week 12 (early virologic response) can determine whether therapy should be continued or not.</description><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Genotype</subject><subject>Graft Survival</subject><subject>Hepacivirus - drug effects</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - surgery</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Infectious diseases</subject><subject>Interferon-alpha - adverse effects</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Liver Transplantation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>Ribavirin - adverse effects</subject><subject>Ribavirin - therapeutic use</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>0954-691X</issn><issn>1473-5687</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkMFqHDEMhk1pabZp36AUX3qcRLYntqe3sKRJIaWXFnobNB45O40zHmxvln2TPG4dsnShCEkH_f8v-Bj7KOBMQGfOv19dn8EAQpGSVnqjpbev2Eq0RjUX2prXbAXdRdvoTvw-Ye9y_gMgjBLmLTsRVgtjrFqxp8u5TI9TwsDLhhIue-5j4oncNiWaC9_QgmUqU-Zrjr5Q4mF6rLMknPMScC71HOcvPG9zwWmmkde4GOLd5GpMXuKciVd7ooClXkvkdzTHsl-Iy3PFcR6POix8R3TPhXzP3ngMmT4c9in79fXq5_qmuf1x_W19eds4ZUE0CF5349CBtR5bLbS2KEdn9UCWVOdatAa70eEAGp3EgdSo5ajGoTIg36pT1r7kuhRzTuT7JU0PmPa9gP4ZdF9B9_-DrrZPL7ZlOzzQeDQdyFbB54MAs8PgKy435X86Ca01Vsrj_10MlW6-D9sdpX5DGMqmB4BWGmUaCWBrATS1hVB_ARVAmzM</recordid><startdate>200808</startdate><enddate>200808</enddate><creator>Raziorrouh, Bijan</creator><creator>Jung, Maria-Christina</creator><creator>Schirren, Carl Albrecht</creator><creator>Loehe, Florian</creator><creator>Thiel, Manfred</creator><creator>Nitschko, Hans</creator><creator>Diepolder, Helmut</creator><creator>Ulsenheimer, Axel</creator><creator>Heeg, Malte</creator><creator>Zachoval, Reinhart</creator><creator>Gruener, Norbert Hubert</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200808</creationdate><title>Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12</title><author>Raziorrouh, Bijan ; Jung, Maria-Christina ; Schirren, Carl Albrecht ; Loehe, Florian ; Thiel, Manfred ; Nitschko, Hans ; Diepolder, Helmut ; Ulsenheimer, Axel ; Heeg, Malte ; Zachoval, Reinhart ; Gruener, Norbert Hubert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3801-a0f69db9088fa461668a2dc86be8e39c4a87a9dcab06ac2abe3d62d3db186ef43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Genotype</topic><topic>Graft Survival</topic><topic>Hepacivirus - drug effects</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - surgery</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Infectious diseases</topic><topic>Interferon-alpha - adverse effects</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Liver Transplantation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>Ribavirin - adverse effects</topic><topic>Ribavirin - therapeutic use</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raziorrouh, Bijan</creatorcontrib><creatorcontrib>Jung, Maria-Christina</creatorcontrib><creatorcontrib>Schirren, Carl Albrecht</creatorcontrib><creatorcontrib>Loehe, Florian</creatorcontrib><creatorcontrib>Thiel, Manfred</creatorcontrib><creatorcontrib>Nitschko, Hans</creatorcontrib><creatorcontrib>Diepolder, Helmut</creatorcontrib><creatorcontrib>Ulsenheimer, Axel</creatorcontrib><creatorcontrib>Heeg, Malte</creatorcontrib><creatorcontrib>Zachoval, Reinhart</creatorcontrib><creatorcontrib>Gruener, Norbert Hubert</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>European journal of gastroenterology & hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raziorrouh, Bijan</au><au>Jung, Maria-Christina</au><au>Schirren, Carl Albrecht</au><au>Loehe, Florian</au><au>Thiel, Manfred</au><au>Nitschko, Hans</au><au>Diepolder, Helmut</au><au>Ulsenheimer, Axel</au><au>Heeg, Malte</au><au>Zachoval, Reinhart</au><au>Gruener, Norbert Hubert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12</atitle><jtitle>European journal of gastroenterology & hepatology</jtitle><addtitle>Eur J Gastroenterol Hepatol</addtitle><date>2008-08</date><risdate>2008</risdate><volume>20</volume><issue>8</issue><spage>778</spage><epage>783</epage><pages>778-783</pages><issn>0954-691X</issn><eissn>1473-5687</eissn><abstract>OBJECTIVESRecurrent hepatitis C virus (HCV) infection after liver transplantation (LT) is a major cause of transplant failure in HCV-positive patients. We retrospectively assessed the efficacy and safety of antiviral therapy and determined the factors influencing sustained virologic response (SVR) in LT recipients.
METHODSBetween 1998 and 2007, we treated 36 LT recipients for hepatitis C cirrhosis and subsequent HCV recurrence (27 genotype 1 and 9 genotypes 2/3) with pegylated interferon α-2a (180 μg/week), pegylated interferon α-2b (1.5 μg/kg per week), or standard interferon α-2b (3 MIU 3X/week) plus ribavirin (600–1200 mg/day) for 48 weeks.
RESULTSSVR was achieved in seven of 27 (26%) of genotype 1 patients versus nine of nine (100%) genotype 2/3 patients (P=0.0001). Early virologic response at week 12 was associated with permanent viral clearance. Side effects included cytopenia and acute hearing loss, but rate of therapy withdrawal and dose reduction was low.
CONCLUSIONCombination therapy in patients with HCV reinfection after LT yields an excellent SVR rate in genotype 2/3 patients, but remains unsatisfactory in genotype 1 patients. Virologic response at week 12 (early virologic response) can determine whether therapy should be continued or not.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>18617783</pmid><doi>10.1097/MEG.0b013e3282f762f8</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-691X |
| ispartof | European journal of gastroenterology & hepatology, 2008-08, Vol.20 (8), p.778-783 |
| issn | 0954-691X 1473-5687 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_MEG_0b013e3282f762f8 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Biological and medical sciences Drug Administration Schedule Drug Therapy, Combination Female Gastroenterology. Liver. Pancreas. Abdomen Genotype Graft Survival Hepacivirus - drug effects Hepacivirus - genetics Hepatitis C - drug therapy Hepatitis C - surgery Human viral diseases Humans Immunosuppressive Agents - therapeutic use Infectious diseases Interferon-alpha - adverse effects Interferon-alpha - therapeutic use Liver Transplantation Male Medical sciences Middle Aged Pharmacology. Drug treatments Recurrence Retrospective Studies Ribavirin - adverse effects Ribavirin - therapeutic use Survival Analysis Treatment Outcome Viral diseases Viral hepatitis |
| title | Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T02%3A10%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiviral%20therapy%20for%20recurrent%20hepatitis%20C%20after%20liver%20transplantation:%20sustained%20virologic%20response%20is%20related%20to%20genotype%202/3%20and%20response%20at%20week%2012&rft.jtitle=European%20journal%20of%20gastroenterology%20&%20hepatology&rft.au=Raziorrouh,%20Bijan&rft.date=2008-08&rft.volume=20&rft.issue=8&rft.spage=778&rft.epage=783&rft.pages=778-783&rft.issn=0954-691X&rft.eissn=1473-5687&rft_id=info:doi/10.1097/MEG.0b013e3282f762f8&rft_dat=%3Cpubmed_cross%3E18617783%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18617783&rfr_iscdi=true |